Detalhe da pesquisa
1.
Proposed rituximab biosimilar BCD-020 versus reference rituximab for treatment of patients with indolent non-Hodgkin lymphomas: An international multicenter randomized trial.
Hematol Oncol
; 38(1): 67-73, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31724191
2.
Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial.
Lancet Oncol
; 12(13): 1204-13, 2011 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21992852
3.
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.
Lancet Oncol
; 12(5): 431-40, 2011 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21507715
4.
Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.
Haematologica
; 100(5): e207-10, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25596270